PubMed Health⌕ Search

Biomedical subjects

D Ikić

Publications and source records attributed to D Ikić.

30 records · Page 2Linked to original sources
PubMed1981

The clinical use of human leukocyte interferon in viral infections.

This review presents the results of the clinical use of human leukocyte interferon (HLI) in certain diseases with viral etiology. Viral infections with manifestations in the eye, skin, and/or mucous membranes and in the respiratory system were treated with HLI by local application. HLI was incorporated into ointment, oil suspension, powder, dilution for inhalation, and dilution for subcutaneous and subconjunctival injections. The treatment in some of the diseases yielded statistical results that were highly significant in favor of interferon.

Adolescent↗
PubMed1972

Studies of combined quadruple vaccines against diphtheria, pertussis, tetanus, and typhoid fever: reactogenicity and antigenicity.

Different DPT + typhoid vaccines were produced by two laboratories and tested in the field for untoward local or systemic reactions and in the laboratory for immunogenic properties. The combined DPT and acetone-inactivated and dried typhoid antigen was found to cause more numerous and more severe local and systemic reactions than the DPT and DPT + typhoid (heat-thiomersal) vaccines. The antibody responses to all four antigens in both of the combined DPT + typhoid vaccines were very satisfactory.From the results of these studies it is concluded that quadruple DPT + typhoid vaccine is suitable for use in areas where typhoid fever is a problem and where logistic and other considerations require the use of combined vaccines.

Antibody Formation↗
PubMedDate not supplied

The testing of cell invasiveness in embryonic tissue and in cell culture.

The subcutis of 11-day-old chick embryos, 15- to 18-day-old mouse embryos and the skin muscle tissue of human fetus were stretched on lens paper in a Petri dish and seeded with a piece of LED-Widr or HDC cell sheet. Mem + 10% FCS was added. After three days incubation the material was fixed, sectioned and H-E stained. In the second part of our investigation several cell lines were prepared on cover slips. When confluent, the cultures were inoculated with 1-2 drops of cell suspension of another cell line. Three days after the seeding of cell suspension on the confluent cell sheet the cultures were fixed and stained. It can be seen in the organ cultures that LED-Widr cells closely adhere to the embryonic tissue which in some places they are invading. In tissue culture examination we found that heteroploid cells seeded on a confluent sheet of diploid cells adhered but that a diploid cell seeded on epithelial-like heteroploid cells would not adhere. The testing of invasiveness in embryonic tissue in organ culture showed that it can be a useful model. By seeding suspended cells of fibroblast lines on a confluent sheet of heteroploid cell lines their contact inhibition or their invasive ability can be determined. The seeding of heteroploid cell lines on diploid cell lines can be used as a model for the study of the mechanism of invasion into normal tissue and for the in vitro study of invasion inhibiting properties of certain substances.

Animals↗
PubMedDate not supplied

Attenuation of influenza A/New Jersey/76 virus strain, preparation of live vaccine and vaccine reactogenicity in volunteers.

The NIB-3 strain (a recombinant of influenza A/New Jersey/76 and X-31 strains) was further attenuated by nine egg passages at 28 degrees C for the purpose of obtaining a "cold-adapted variant" suitable for preparation of live freeze-dried vaccine with 5% peptone. The vaccine with two infectivity titres, of 7 and 6 log EID50/dose respectively, administered intranasally, was studied in a double-blind placebo-controlled field trial. The reactogenicity of the vaccine was evaluated on the basis of fever reactions during the first three days after vaccination and by the detection of local virus recovery from throat swabs taken on the first four days after vaccination. The majority of vaccines had no fever. On the first day following vaccination the proportions of persons with low-grade fever (up to 37.4 degrees C) were the same in the groups given placebo and vaccine with 6 log EID50/dose respectively. In the group vaccinated with 7 log EID50/dose there were 8% more persons with low-grade fever than in the group given placebo, but this difference was not significant (P greater than 0.05). On the second and the third day after vaccination there was no difference between the proportions of persons with low-grade fever in all the three groups. The highest number of virus isolations, i.e. 26%, was found in persons vaccinated with 7 log EID50/dose, 72 h after vaccination. In the placebo group the virus was not isolated from any person during the entire course of the study.

Adaptation, Physiological↗
PubMedDate not supplied

HI antibody response in volunteers vaccinated with live influenza A/New Jersey/76 vaccine.

Live freeze-dried influenza A/New Jersey/76 vaccine prepared from the "cold-adapted variant" of NIB-3 strain. Three groups of about 50 persons were included in a double-blind placebo-controlled field trial. One group received the vaccine with 7 log EID50/dose, the other 6 log EID50/dose and the third received placebo. One half of persons from each group were given a second dose of the corresponding preparation after two weeks. The immunogenicity of the vaccine was evaluated by the determination of HI antibody conversion rate in seronegative persons. The proportion of vacinated persons with seroconversion, regardless of the number of doses, increased with time, and 16 weeks after vaccination reached the maximum value of 0.87 in persons given vaccine with 7 log EID50 per dose and 0.55 in those given 6 log EID50/dose. In twice-vaccinated persons the proportion of seroconversion was higher regardless of the virus titre of the vaccine. The highest proportion of seroconversion (0.93) was recorded in persons vaccinated twice with 7 log EID50/dose 16 weeks after vaccination.

Adaptation, Physiological↗
PubMedDate not supplied

[Interferon in the treatment of solid tumors].

Discovered almost four decades ago, interferons were being investigated as potential anticancer agents from early sixties, because of their antiviral antiproliferative and immunomodulating properties and their relatively modest toxicity. Unlike very good effects on some lymphoproliferative disorders where complete durable remissions were observed, results of their application in solid tumors are not so unambiguous. Among large number of tumors investigated so far, the best, reproducible, although modest, activity was found against melanoma, renal cell carcinoma and Kaposi's sarcoma. There are still many doubts concerning their optimal doses, sequencing and schedules, most probably in combination with other biological response modifiers and/or cytotoxic agents, which have to be clarified in further clinical trials, together with investigation of more reliable biological indicators of response to interferons in vivo.

Humans↗